More about

Interleukin-17

News
April 27, 2021
2 min read
Save

Guselkumab exhibits comparable efficacy to IL-17A, TNF inhibitors for psoriatic arthritis

Guselkumab exhibits comparable efficacy to IL-17A, TNF inhibitors for psoriatic arthritis

Guselkumab is comparable to interleukin-17A and subcutaneous TNF inhibitors for efficacy, and demonstrated a better PASI response relative to other drugs, in patients with psoriatic arthritis, according to a meta-analysis published in Rheumatology.

News
November 26, 2019
4 min read
Save

Novel therapies provide options for patients with spondyloarthritides

Novel therapies provide options for patients with spondyloarthritides

ATLANTA — Certolizumab pegol and bimekizumab were associated with improvements ranging from work productivity to disease activity in patients with spondyloarthritic conditions, according to findings presented in three abstracts at ACR/ARP 2019.

News
November 15, 2019
1 min read
Save

Bimekizumab meets primary, secondary endpoints in phase 3 psoriasis study

Bimekizumab meets primary, secondary endpoints in phase 3 psoriasis study

UCB announced positive results from BE READY, the second of three phase 3 studies to report on bimekizumab this year.

News
November 11, 2019
3 min read
Save

Guselkumab efficacious for joint, skin symptoms, physical function in PsA

Guselkumab efficacious for joint, skin symptoms, physical function in PsA

ATLANTA — Guselkumab, administered either every 4 or 8 weeks, is efficacious for joint and skin symptoms, as well as physical function and quality of life, among patients with active psoriatic arthritis who are biologic-naive or previously received TNF inhibitors, according to data presented at ACR/ARP 2019.

News
October 29, 2019
2 min read
Save

Top stories for World Psoriasis Day: ‘More than a day for awareness’

Top stories for World Psoriasis Day: ‘More than a day for awareness’

Since 2004, World Psoriasis Day has been celebrated on Oct. 29.

News
October 18, 2019
1 min read
Save

UCB reports bimekizumab response rates superior to Stelara in psoriasis

UCB reports bimekizumab response rates superior to Stelara in psoriasis

Treatment with bimekizumab, an interleukin-17A and IL-17F inhibitor in adults with chronic plaque psoriasis, resulted in at least a 90% improvement in the Psoriasis Area and Severity Index and Investigator Global Assessment score of clear or almost clear, according to phase 3 results from the development program BE VIVID by UCB.

News
October 11, 2019
4 min read
Save

4-year data demonstrate safety, efficacy of Ilumya in plaque psoriasis

4-year data demonstrate safety, efficacy of Ilumya in plaque psoriasis

The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label reSURFACE1 trial, according to data presented at the European Academy of Dermatology and Venereology Congress.

News
September 12, 2019
2 min read
Save

Guselkumab shows superior long-term efficacy vs. secukinumab based on PASI 90

Guselkumab shows superior long-term efficacy vs. secukinumab based on PASI 90

A significantly greater proportion of patients with psoriasis receiving guselkumab achieved a 90% reduction or more in the Psoriasis Area and Severity Index at week 48 than those receiving secukinumab, according to researchers in The Lancet.

News
August 21, 2019
1 min read
Save

Four popular headlines to highlight Psoriasis Action Month

Four popular headlines to highlight Psoriasis Action Month

Earlier this month, Healio Dermatology posted a compilation of eight popular reads to kickoff Psoriasis Action Month in psoriasis research, advocacy and FDA news.

News
August 13, 2019
2 min read
Save

Taltz meets primary, secondary endpoints in head-to-head trial

Taltz meets primary, secondary endpoints in head-to-head trial

Taltz met the primary and secondary endpoints at week 12 in a phase 4 head-to-head study comparing its efficacy and safety vs. Tremfya in patients with moderate to severe plaque psoriasis, according to an announcement from Eli Lilly and Company.

View more